Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
Public ClinicalTrials.gov record NCT02742090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 (Umbralisib) in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main objective of this study is to determine the progression free survival of umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase) inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta inhibitors (idelalisib, duvelisib, other).
Study identification
- NCT ID
- NCT02742090
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 20, 2016
- Primary completion
- Jun 9, 2021
- Completion
- Jun 9, 2021
- Last update posted
- Jul 2, 2024
2016 – 2021
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | Huntsville | Alabama | 35805 | — |
| TG Therapeutics Investigational Trial Site | Washington D.C. | District of Columbia | 20007 | — |
| TG Therapeutics Investigational Trial Site | Fort Myers | Florida | 33916 | — |
| TG Therapeutics Investigational Trial Site | St. Petersburg | Florida | 33705 | — |
| TG Therapeutics Investigational Trial Site | Kansas City | Missouri | 64132 | — |
| TG Therapeutics Investigational Trial Site | Lebanon | New Hampshire | 03756 | — |
| TG Therapeutics Investigational Trial Site | Hackensack | New Jersey | 07601 | — |
| TG Therapeutics Investigational Trial Site | New Hyde Park | New York | 11042 | — |
| TG Therapeutics Investigational Trial Site | New York | New York | 10032 | — |
| TG Therapeutics Investigational Trial Site | Rochester | New York | 14642 | — |
| TG Therapeutics Investigational Trial Site | Durham | North Carolina | 27710 | — |
| TG Therapeutics Investigational Trial Site | Hershey | Pennsylvania | 17033 | — |
| TG Therapeutics Investigational Trial Site | Philadelphia | Pennsylvania | 19146 | — |
| TG Therapeutics Investigational Trial Site | Nashville | Tennessee | 37203 | — |
| TG Therapeutics Investigational Trial Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02742090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02742090 live on ClinicalTrials.gov.